Michael R. Hayden - 10 Nov 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 10 Nov 2026
Net transaction value: +$148,200
SEC form: 4
Accepted by SEC: 13 Nov 2026, 16:19:56 UTC
Prior SEC filing: 24 Aug 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Michael R. Hayden

Filing notes and source

Key filing fact

Michael R. Hayden filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 13 Nov 2026.

Key facts

This page summarizes Michael R. Hayden's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Nov 2026, 16:19.

Change

Previous filing in this sequence was filed on 24 Aug 2026.
Current net transaction value: +$148,200.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001352908 Primary reporting owner

Hayden Michael R

Relationship: Director
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Michael R. Hayden
Signature date: 13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Purchase

Transaction value: $148,200
Shares: +5,000
Change %: +23%
Price: $29.64
Shares after: 27,000
Date: 10 Nov 2026
Ownership: by Spouse
Footnotes: F1, F2

IONS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 54,298
Date: 10 Nov 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.60 to $29.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.

Footnote F2

The number of securities indirectly owned by the reporting person was reported as 24,000 shares on the Form 4 filed July 31, 2026. The correct number of securities indirectly owned by the reporting person as of July 31, 2026, was 22,000 shares. The amount reported on this Form 4 reflects the reporting person's correct indirect beneficial ownership.